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Summary
To identify genetic events underlying the genesis and progression of multiple myeloma (MM), we conducted a high-resolu-
tion analysis of recurrent copy number alterations (CNAs) and expression profiles in a collection of MM cell lines and out-
come-annotated clinical specimens. Attesting to themolecular heterogeneity ofMM, unsupervised classification using non-
negative matrix factorization (NMF) designed for array comparative genomic hybridization (aCGH) analysis uncovered
distinct genomic subtypes. Additionally, we defined 87 discreteminimal common regions (MCRs) within recurrent and highly
focal CNAs. Further integration with expression data generated a refined list of MM gene candidates residing within these
MCRs, thereby providing a genomic framework for dissection of disease pathogenesis, improved clinical management, and
initiation of targeted drug discovery for specific MM patients.Introduction
Multiple myeloma (MM) is characterized by clonal proliferation
of plasma cells in the bone marrow, usually with elevated serum
and urine monoclonal paraprotein and associated end organ se-
quelae. MM is the second most frequent hematological cancer
in the US after non-Hodgkin’s lymphoma. MM is typically pre-
ceded by an age-progressive condition termed monoclonal
gammopathy of undetermined significance (MGUS), a condition
present in 1% of adults over the age of 25 that progresses to
MM at a rate of 0.5%–3% per year (Bergsagel et al., 2005;
Kyle and Rajkumar, 2004; Mitsiades et al., 2004). MM remains
largely incurable despite high-dose chemotherapy with stemCANCER CELL 9, 313–325, APRIL 2006 ª2006 ELSEVIER INC. DOI 10.10cell support. Novel agents such as thalidomide, the immunore-
gulator Revlimid, and the proteasome inhibitor bortezomib can
achieve responses in patients with relapsed and refractory
MM; however, the median survival remains at 6 years, with
only 10% of patients surviving at 10 years (Barlogie et al.,
2004; Rajkumar and Kyle, 2005; Richardson et al., 2005).
Significant effort has been directed toward the identification
of the molecular genetic events in this malignancy with the goals
of improving early detection and providing new therapeutic tar-
gets. Unlike most hematological malignancies and more similar
to solid tissue neoplasms, MM genomes are typified by numer-
ous structural and numerical chromosomal aberrations (Kuehl
and Bergsagel, 2002). Reflecting the increasing genomicS I G N I F I C A N C E
MM is the second most common hematological malignancy and remains incurable. Effective targeted therapies require detailed
knowledge of the spectrum of genetic lesions governing MM pathogenesis. This study provides a comprehensive and integrated
view of recurrent amplifications and deletions and their associated gene expression alterations. This integration, coupled with this
high-resolution aCGH platform, delimited a tractable number of candidate genes for enlistment into functional validation and ulti-
mately drug discovery. Importantly, unsupervised NMF-based classification of the MM genome profiles stratified MM into specific sub-
groups in which the classical hyperdiploid MM was further subdivided into two subgroups with distinct clinical outcomes. Thus, MM is
a molecularly heterogeneous disease in which distinct loci can be linked to clinical behavior and prognosis.16/j.ccr.2006.03.019 313
A R T I C L Einstability that characterizes disease progression, metaphase
chromosomal abnormalities can be detected in only one-third
of newly diagnosed patients but are evident in the majority of pa-
tients with end-stage disease (Fonseca et al., 2004). Yet, apply-
ing DNA content or interphase fluorescence in situ hybridization
(FISH) analyses, aneuploidy and translocations are detectable in
virtually all subjects with MM and even MGUS (Bergsagel and
Kuehl, 2001; Chng et al., 2005). Extensive molecular (Kuehl
and Bergsagel, 2002; Shaughnessy and Barlogie, 2003), cyto-
genetic (Bergsagel and Kuehl, 2001; Debes-Marun et al.,
2003; Sawyer et al., 1998), and chromosomal CGH (Avet-Loi-
seau et al., 1997; Cigudosa et al., 1998) analyses have uncov-
ered a number of recurrent genetic alterations in MM and its pre-
cursor MGUS, some of which have been linked to disease
pathogenesis and clinical behavior.
Chromosomal translocations involving the IgH locus are seen
in most MM cell lines, consistent with MM’s origin from antigen-
driven B cells in postgerminal centers (Kuehl and Bergsagel,
2002). Five recurrent loci/genes are commonly juxtaposed to
the powerful IgH enhancer locus elements, including 11q13
(CCND1), 4p16 (FGFR3/WHSC1), 6p21 (CCND3), 16q23
(MAF), and 20q11 (MAFB), resulting in deregulated expression
of these target genes in neoplastic plasma cells (Bergsagel
and Kuehl, 2005). Such translocations, present in MGUS, ap-
pear central to MM genesis, whereas progression is associated
with mutational activation of NRAS or KRAS oncogenes and in-
activation of CDKN2A, CDKN2C, CDKN1B, and/or PTEN tumor
suppressor genes (TSGs). Late mutational events involve inacti-
vation of TP53 and secondary translocations involving MYC
(Kuehl and Bergsagel, 2002).
Two oncogenic pathways have been hypothesized for MGUS/
MM pathogenesis. Hyperdiploid MM involves multiple trisomies
of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, whereas nonhy-
perdiploid MM is associated with prevalent IgH translocations
(Bergsagel et al., 2005; Cremer et al., 2005; Fonseca et al.,
2004). Ploidy level also impacts prognosis: nonhyperdiploidy
imparts short survival (Fonseca et al., 2004) that can be counter-
acted by the presence of trisomies involving chromosomes 6, 9,
11, and 17. Deletion of chromosome 13, especially band 13q14,
is commonly observed in nonhyperdiploid MM and confers high
risk (Fonseca et al., 2004). Expression profiling has been used to
define molecular subgroups of MM with clinical correlates, and
a novel TC (translocation/cyclin D) classification of MM has been
proposed (Bergsagel et al., 2005). Gene expression profiles of
511 outcome-annotated MM cases have pointed to amplifica-
tion at 1q21 as an independent predictor of outcome (F.Z. and
J.D.S., unpublished data). While these antecedent efforts have
led to important insights into the pathogenesis and clinical be-
havior of MM, these numerous recurrent genomic alterations
point to many undefined genetic elements that may prove rele-
vant to disease initiation, progression, and drug responsive-
ness. However, while recurrent chromosomal gains have been
mapped to 1q, 3q, 9q, 11q, 12q, 15q, 17q, and 22q and recur-
rent losses to 6q, 13q, 16q, Xp, and Xq, the presumed cancer-
relevant targets in these loci are not known.
This study sought to develop a more thorough molecular view
of MM pathogenesis through an integrated analysis of the can-
cer-associated alterations on the DNA and RNA levels in clini-
cally annotated material. This MM oncogenomic analysis identi-
fied genetic elements with strong biological and clinical
correlates as evidenced by their common targeting in other314tumor types, correlation with survival, and presence of known
oncogenes and TSGs or their homologs not previously impli-
cated in MM pathogenesis. The high-resolution view afforded
here also provides an efficient entry point for the discovery of
new MM-relevant genes.
Results
Unsupervised classification of MM genomic features
identifies distinct patient subgroups
High-resolution aCGH methodology was used to catalog copy
number alterations (CNAs) in the genomes of CD138+-enriched
plasma cells (>90% CD138+CD452) derived from 67 newly diag-
nosed MM patients prior to treatment (Table S1 in the Supple-
mental Data available with this article online). This data set re-
vealed a highly rearranged MM genome, harboring large
numbers of distinct CNAs. Since genomic alterations hold the
potential to identify genetic events playing direct roles in disease
pathogenesis and progression (Aguirre et al., 2004; Pollack
et al., 2002; Tonon et al., 2005), we sought to determine whether
MM genomic profiles could specify meaningful genetic and clin-
ical subgroups by unsupervised methodologies. To this end, we
developed an algorithm based on nonnegative matrix factoriza-
tion (NMF) (Brunet et al., 2004) (Experimental Procedures; C.B.
and L.C., unpublished data), designed to extract distinctive ge-
nomic features from aCGH profiles, hereafter designated as
gNMF. Briefly, gNMF was performed on aCGH data after trans-
forming to nonnegative values, and gNMF consensus matrices
were generated (Figure S1). Ranks K = 2, 3, and 4 generated ma-
trices showing stable cluster assignments suggesting the exis-
tence of up to four distinct genomic patterns among the 67
MM samples.
The rank K = 2 classification divided these 67 samples into
a ‘‘kA’’ subgroup (n = 38) characterized by odd-chromosome
gains and a ‘‘kB’’ subgroup (n = 29) characterized by loss of
chromosomes 1p, 8p, 13, and 16q and amplification of ch1q
(Figure 1A). Thus, the K = 2 classification yields a grouping rem-
iniscent of the well-recognized hyperdiploid (e.g., odd-chromo-
some gain pattern) and nonhyperdiploid subclasses. However,
when correlated with clinical outcome data, the kA (hyperdip-
loid) subgroup showed only a trend toward improved survival
over kB (nonhyperdiploid) subgroup (Figure 1B; see below),
prompting assessment of further genomic subclasses within
kA and kB. Indeed, with rank K = 4 matrix, these 67 MM samples
were subdivided by gNMF into four distinct molecular sub-
classes, k1–k4 (Figure 2A). All 21 k1 and 16 k2 samples be-
longed to the kA subgroup, while all 13 k3 and 16 of 17 k4 sam-
ples were in the kB subgroup. In other words, unbiased
genome-wide classification of genomic alterations provided
molecular evidence that MM is a heterogeneous disease, and
that the traditional hyperdiploid MM class consists of two mo-
lecular subclasses.
Definition of a subclass of hyperdiploid MM with poor
prognosis
Although considered a relatively good prognosis group, hyper-
diploid MM patients (kA subgroup) did not uniformly survive lon-
ger in our cohort (Figure 1B; log rank test p = 0.25 and 0.10 for
event-free survival [EFS] and overall survival [OS], respectively).
Since gNMF classification with K4 rank showed that kA wasCANCER CELL APRIL 2006
A R T I C L EFigure 1. gNMF classification with rank K = 2 iden-
tifies two subgroups, kA and kB, reminiscent of
the MM hyperdiploid/nonhyperdiploid sub-
groups
A: aCGH profiles of 67 clinically annotated pri-
mary tumors were subjected to NMF analyses
(1000 repetitions). With rank K = 2, two distinct
subgroups, kA and kB, were identified (y axis),
and centroids of each group are shown. x axis
represents genomic map order (from ch1 to
ch22). The colors denote gained (red), euploid
(yellow/green), or deleted (blue) chromosome
material.
B: KM event-free survival (EFS; left) and overall
survival (OS; right) curves for 64 MM patients
demonstrating no significant difference in sur-
vival (p = 0.25 and 0.1, respectively) when di-
vided into subgroups kA versus kB.composed of k1 and k2 subclasses, we evaluated outcomes of
patients in k1 and k2. Here, Kaplan-Meier (KM) curves for k1 (n =
21) and k2 (n = 16) patients were generated for EFS and OS with
median follow-up of 43.4 months post-TT2 regimen (Figure 2B).
Clearly, k1 possessed a significant EFS advantage with a trend
for better OS over k2 (log rank test p = 0.012 for EFS and p =
0.12 for OS), indicating that the genomic heterogeneity inCANCER CELL APRIL 2006hyperdiploid MM holds biological relevance and embedded
within it are molecular events dictating clinical behavior of the
disease.
As the first step toward elucidating genetic determinants of
outcome in hyperdiploid MM, we exploited the high degree of
relatedness between k1 and k2 genomes to uncover clinically
relevant CNAs (Figure 2A). Comparison of k1 versus k2 genomicFigure 2. gNMF classification with rank K = 4 iden-
tifies four distinct subgroups
A: aCGH profiles of 67 clinically annotated pri-
mary tumors were subjected to NMF analyses
(1000 repetitions). y axis indicates the four sub-
groups identified by NMF. The x axis coordinates
represent genomic map order (from ch1 to
ch22). The colors denote gained (red), euploid
(yellow/green), or deleted (blue) chromosome
material.
B: KM event-free survival (EFS; left) and overall
survival (OS; right) curves for 64 MM patients for
k1 and k2 subgroups. k1 shows significantly better
event-free survival than k2 (p = 0.012), while OS
did not reach statistical significance (p = 0.12).315
A R T I C L EFigure 3. Distribution of genes differentially expressed between k1 and k2 subgroups and residing on chromosomes 1q or 13q
Expression probe sets are mapped to their respective genomic positions and are shown as vertical hash marks along the bottom of each plot. Black hash
marks denote genes found to be differentially expressed between k1 and k2 subgroups by SAM. Count of significant genes within a moving 10 Mb window
is shown (y axis), and asterisks indicate the center of regions of significant clustering (p < 0.05 by permutation testing). The significant region spans approxi-
mately 143–158 Mb for ch1 (A) and 38–50 Mb for ch13 (B), though boundaries are approximates based on the moving window width.patterns (Experimental Procedures) identified several prominent
features, which include the following: (1) ch11 gain in 20/21 k1
versus only 6/16 k2 samples (p < 0.001, c2 test); (2) gains of
ch1q in 9/16 k2 versus 0/21 k1 samples (p < 0.001); and (3)
ch13 loss in 10/16 k2 versus only 4/21 k1 samples (p = 0.019).
Consistently, these three features were among the major com-
ponents defined by gNMF in the K4 classification (Figure 2A).
Together, our analysis suggests that, among hyperdiploid MM,
ch11 gain confers a more favorable outcome, whereas ch1q
gain and ch13 loss drive poor outcome.
To mine further for poor survival ch1q and ch13 genes in k2,
the significance analysis of microarrays (SAM) approach (Tusher
et al., 2001) was applied to corresponding transcriptome pro-
files. Significantly increased expression in k2 versus k1 was
noted for 111/2210 probes (95 genes) mapping to ch1q
(FDR = 15%) (Table S2), and decreased expression in k2 versus
k1 for 48/1163 probes (46 genes) mapping to ch13 (FDR = 15%)
(Table S3). In both ch1q and ch13 cases, SAM-significant
probes clustered in specific chromosomal bands. We therefore
tested whether subregions of ch1q and ch13 were significantly
enriched for differentially expressed genes by counting signifi-
cant genes in a 10 Mb moving window, and testing for signifi-
cance by permutation of gene position (Tonon et al., 2005).316This approach revealed a marked enrichment in overexpressed
genes residing at 1q21–q23, spanning approximately 143–158
Mb (Figure 3A; p < 0.05), a region that is particularly notable,
as it encompasses two of our high-priority minimal common re-
gions (MCRs) associated with poor survival (see below). The 1q
genes upregulated in the poor prognosis k2 subgroup included
several encoding cancer-relevant activities (Table S2; Discus-
sion). Analogous studies of ch13 showed significant enrichment
of underexpressed genes residing at 13q14 between 38 and 50
Mb (Figure 3B; p < 0.05), a region known to sustain the highest
frequency of LOH on ch13 in MM and including RB1 (Elnenaei
et al., 2003). Within this region, comparison between gene ex-
pression in k1 and k2 groups identifies additional candidate
TSGs (Table S3; Discussion).
In summary, molecular classification based on genomic fea-
tures provided clear evidence that hyperdiploid MM is a geneti-
cally heterogeneous disease, and that a poor prognosis subset
of hyperdiploid MM patients can be identified by the presence of
ch1q gain and/or ch13 loss. In addition to the translational impli-
cations, the stratification of hyperdiploid MM into two outcome-
correlated subclasses itself serves as strong validation of appli-
cation of this gNMF algorithm for molecular classification of
aCGH profiles.CANCER CELL APRIL 2006
A R T I C L EFigure 4. Summary of genomic profiles of MM and recurrence of chromosomal alterations in primary MM tumors
Integer-value recurrence of CNAs across the samples in segmented data (y axis) is plotted for each probe evenly aligned along the x axis in chromosomal
order. Dark red or green bars denote the number of samples with gain or loss of chromosome material, and bright red or green bars represent the number of
samples showing amplification or deletion (Experimental Procedures). Asterisks show focal deletions of the kappa (2p12), IgH (14q32), and lambda chain
(22q11) loci physiological in B cell postgerminal center neoplasms.Recurrent and focal CNAs in the MM genome with
potential biological and clinical significance
In addition to genomic classification and identification of prog-
nosis-associated loci, the high-definition picture of the MM ge-
nome enabled definition of recurrent CNAs with strong involve-
ment in MM pathogenesis. The performance features of the
aCGH platforms (Brennan et al., 2004) and segmentation analy-
sis (Aguirre et al., 2004; Tonon et al., 2005) readily identified
large regional changes. The skyline recurrence plot (Figure 4)
mirrors well the frequencies of previously reported chromo-
somal gains of 1q, 3, 5, 7, 9, 11, 15, 19, and 21, and losses of
1p and 13 (Avet-Loiseau et al., 1997; Cigudosa et al., 1998;
Cremer et al., 2005; Fonseca et al., 2004). In addition, these sur-
veys also captured focal, recurrent, high-amplitude CNAs pres-
ent in both cell lines and primary tumor specimens (Figure S2A).
Analysis of 358 distinct CNAs across the MM tumor collection
(n = 67) and MM cell lines collection (n = 43) delimited 298
MCRs (Figure S2B and data not shown), which were further fil-
tered down to 87 prioritized MCRs based on the criteria of pres-
ence in primary tumors and occurrence of at least one high-
amplitude event (log2 ratio > 0.8). These 87 MCRs comprised
47 amplifications (Table 1) and 40 deletions (Table 2), spanning
a median size of 0.89 Mb with an average of 12 known genes.
That these ‘‘high-priority’’ MCRs possess high disease rele-
vance is reflected by (1) consistent verification by real-time
quantitative PCR (QPCR) in all randomly assayed high-priority
MCRs and by FISH in selected cases (Tables 1 and 2, asterisks;
Figure S3 and data not shown), and (2) inclusion of all signature
MM loci of known pathogenetic relevance such as deletion of
a region including the TP53 tumor suppressor and focal amplifi-
cations of areas including the hepatocyte growth factor (HGF)
and the MYC and ABL1 oncogenes.
Integrated copy number and expression analysis
identified known and potential cancer genes in MM
pathogenesis
As copy number alterations function to alter expression of resi-
dent genes (Aguirre et al., 2004; Platzer et al., 2002; Tonon et al.,
2005), we conducted an integrated RNA expression analysis by
the gene weight measure as described (Aguirre et al., 2004; Hy-
man et al., 2002). First, for each gene residing within an amplified
MCR, we asked whether its expression showed a copy number-CANCER CELL APRIL 2006correlated pattern by comparing the mRNA levels in tumors with
and without CNAs in the region of interest. In addition, modeling
after bona fide oncogenes, such as MYC, whose expressions
are known to be dysregulated by mechanisms other than gene
dosage alteration, we also compared expression of the gene
in tumors with or without CNAs, relative to normal plasma cells,
respectively (Experimental Procedures). Genes showing this
‘‘oncogene-like’’ expression pattern—namely copy number-
correlated expression and significant overexpression in tumors
without amplification versus normal plasma cells—were consid-
ered high-probability candidates targeted for amplification in
these MCRs during MM development.
By such stringent criteria, approximately 30% of the 2151
genes residing in the high-priority MCRs were considered
strong candidates. These included genes with credentialed
roles in MM pathogenesis such as MYC, MCL1, IL6R, HGF,
and ABL1 (Table 1 and data not shown), as well as many func-
tionally diverse genes with no known link to MM development.
Particularly noteworthy are several E3 ubiquitin ligase genes, in-
cluding the anaphase promoting complex subunit 2 (ANAPC2),
F box protein 3 (FBXO3), F box protein 9 (FBXO9), SMAD-spe-
cific E3 ubiquitin protein ligase 2 (SMURF2), and huntingtin inter-
acting protein 2 (HIP2). Amplification/expression was observed
for molecular chaperones including chaperonin containing
TCP1, subunit 3 (g) (CCT3), Der1-like domain family, member
1 (DERL1), DNAJ (HSP40) homolog, subfamily C, member 1
(DNAJC1), and the cochaperone adaptor (CDC37), which has
been shown to be oncogenic in transgenic mice (Stepanova
et al., 2000). There was deregulation of many ribosome biogen-
esis and protein synthesis genes, including ribosomal protein-
encoding genes RBM8A and RPL18, and translational control
gene EEF2 (Table 1). Thus, we conclude that integrated
copy number and expression analysis provides an efficient
first-pass means of distinguishing bystanders from potential
cancer gene(s) target(s) within any given CNAs; as previously
observed (Aguirre et al., 2004; Pollack et al., 2002; Tonon
et al., 2005).
High-priority MCRs define loci with biological and
prognostic relevance
To determine whether any high-priority MCRs (Tables 1 and 2)
possessed prognostic relevance, we compared the survival317
A R T I C L ETable 1. High-confidence MCRs in multiple myeloma: Gains and amplifications
MCR recurrence
MCRs Gains/losses Amps/dels
Cytogenetic
band
Position
(Mb)
Size
(Mb)
Max/min
value
Known
genes % Tumors
Cell
lines Tumors
Cell
lines
Candidate
genes miRNA
Integration
sites
1q21.1–1q22*,A 142.60–152.10 9.50 2.46 228 55.5 26 35 14 27 MCL1, IL6R, PSMD4,
PSMB4, UBE2Q,
UBAP2L, RBM8A,
RPS27, PIAS3,
POLR3C, HIST2H2AA,
LASS2, MRPL9,
JTB, HAX1,
SHC1, APH-1A,
BCL9, ZNF364
Dkmi7, Rorc,
NKI-6, Dkmi8
1q22 152.73–153.27 0.53 1.44 21 53.6 24 35 13 28 SSR2, MAPBPIP, CCT3,
MEF2D, C1orf85
hsa-mir-9-1 Evi53
1q43-1q44 236.73–245.42 8.69 0.93 94 35.5 20 19 12 12 FH, HNRPU, TFB2M
2p25.1 11.35–11.68 0.33 1.48 3 13.6 7 8 2 5
2p16.1 55.68–56.01 0.32 1.16 4 11.8 8 5 3 2 SMEK2, MGC15407
2q35 219.08–219.44 0.36 1.02 11 9.09 7 3 4 2 BCS1L hsa-mir-26b
3q27.1–3q27.2 185.53–187.13 1.60 0.90 19 47.3 35 17 9 5 POLR2H, EIF4G1
4p14–4p12 39.60–48.73 9.12 0.88 45 6.36 7 0 2 0 HIP2, SCC-112,
OCIAD1, RHOH,
UCHL1, TMEM33
4q22.3–4q24 95.84–104.04 8.20 1.83 35 9.09 8 2 2 1 PPP3CA, H2AFZ,
SLC39A8
Evi157
5p12 42.76–43.16 0.41 0.87 5 43.6 35 13 10 6 Evi124
5q13.2–5q13.3* 73.12–76.06 2.94 1.26 19 36.4 31 9 8 4 TINP1, HMGCR,
COL4A3BP, POLK
Evi19
5q14.1 77.48–79.97 2.49 1.26 20 35.5 31 8 8 4 SCAMP1, ARSB, JMY,
MTX3, PAPD4
5q31.3 140.55–140.66 0.11 2.30 10 33.6 35 2 14 1 PCDHB10
6p21.32–6p21.32 32.04–32.20 0.16 0.82 11 20.9 14 9 3 6 RDBP, STK19
6p21.1 45.99–53.24 7.25 0.92 53 18.2 13 7 1 2 CD2AP, MUT, FBXO9,
TFAP2B, TMEM14A,
ICK, ELOVL5
hsa-mir-206,
hsa-mir-133b
6q13 70.81–73.68 2.87 0.89 11 15.5 10 7 1 3 SMAP1 hsa-mir-30c-2,
hsa-mir-30a-5p
7p14.3 30.89–33.74 0.26 1.36 15 42.7 30 17 10 5 LSM5, FKBP9, NT5C3,
PTHB1, KBTBD2, RP9
7p12.2* 50.25–50.53 0.28 2.06 3 43.6 30 18 7 6
7q21.11 79.93–81.24 1.30 1.32 4 43.6 30 18 6 6 HGF
7q21.12 86.03–87.18 1.15 1.85 11 44.5 30 19 6 5 MCFP, DMTF1, ASK,
TP53AP1
7q32.1–7q32.2 126.07–129.78 3.70 1.44 48 50 31 24 13 10 CALU, TNPO3, UBE2H,
ARF5, RBM28, IRF5,
METTL2, CDC26
hsa-mir-129-1,
hsa-mir-182,
hsa-mir-96,
hsa-mir-183,
hsa-mir-335
8q24.12–8q24.13A 120.50–126.52 6.02 0.84 37 20.9 4 19 2 8 DEPDC6, MRPL13,
DERL1, ZHX1,
TATDN1, RNF139,
FBXO32
8q24.21–8q24.3A 128.50–146.20 17.70 2.50 127 24.5 6 21 3 10 MYC, PVT1 hsa-mir-30b,
hsa-mir-30d,
hsa-mir-151
Si22, Dkmi21
9q34.11–9q34.3* 127.35–137.60 10.26 1.61 202 54.5 47 13 14 3 ABL1, CIZ1, NUP188,
SET, ENDOG, SURF1,
SURF2, SURF4,
CAMSAP1, UBADC1,
SDCCAG3, EDF1,
DPP7, ANAPC2,
COBRA1
hsa-mir-199b,
hsa-mir-219-2,
hsa-mir-126
Notch1,
Ppp2r4,
Gfi1b, Evi43
9q34.3 137.62–138.29 0.67 0.82 9 50.9 46 10 11 1 MRPL41, ZMYND19,
EHMT1
10p12.33–10p12.31 17.69–22.09 4.40 1.08 15 14.5 6 10 2 6 DNAJC1
11p13 33.30–34.10 0.81 0.80 8 34.5 32 6 10 3 CD59, FBXO3, M11S1,
HIPK3
Lmo2
11p11.2 46.72–47.34 0.62 1.01 11 41.8 33 13 10 7 ACP2, CKAP5, DDB2 Sfpi1318 CANCER CELL APRIL 2006
A R T I C L ETable 1. Continued
MCR recurrence
MCRs Gains/losses Amps/dels
Cytogenetic
band
Position
(Mb)
Size
(Mb)
Max/min
value
Known
genes % Tumors
Cell
lines Tumors
Cell
lines
Candidate
genes miRNA
Integration
sites
11q13.4–11q14.1 73.40–77.71 4.30 1.27 54 51.8 36 21 6 12 SPCS2, RPS3 hsa-mir-326
11q14.1 77.01–82.85 0.00 1.27 24 51.8 36 21 7 10 PCF11, HBXAP
11q23.3 112.74–122.23 3.47 1.47 112 50.9 35 21 8 12 UBE4A, ATP5L, RPS25,
HMBS, CBL, DDX6,
TRAPPC4, HYOU1,
RNF26
12q24.33 131.00–131.07 0.07 1.23 2 5.45 2 4 1 2
14q11.2 19.41–19.51 0.11 1.33 3 5.45 3 3 3 0
15q24.2 73.45–73.72 0.27 1.49 4 47.3 44 8 18 2 IMP3
16q24.2 86.43–87.13 0.70 0.98 6 8.18 4 5 2 0
17p11.2* 17.62–17.71 0.09 1.13 4 12.7 6 8 1 2 RPL13, PAIP1
17q23.2 53.94–54.69 0.75 0.89 11 17.3 8 11 1 6 MTMR4, FLJ11029,
RAD51C
hsa-mir-301
18q12.1–18q12.2* 30.53–31.95 1.43 1.12 12 26.4 13 16 5 6 ZNF271, P15RS,
SLC39A6
hsa-mir-187 Evi135
18q21.2–18q21.33 51.41–59.71 8.30 1.39 42 29.1 13 19 5 10 MALT1, BCL2, FVT1 hsa-mir-122a Evi36
19p13.3–19p13.2 0.24–11.19 10.96 0.91 320 66.4 47 26 7 14 CDC34, POLRMT,
WDR18, ATP5D,
MUM1, NDUFS7,
RPS15, UQCR,
REXO1, CSNK1G2,
MOBKL2A, MKNK2,
INSR, TIMM13,
MRPL54, EEF2,
MAP2K2, HDGF2,
TICAM1, RPL36,
NDUFA11, CLPP,
SH2D3A, NDUFA7,
RPS28, RAB11B,
EIF3S4, MRPL4,
ICAM1, ICAM3,
CDC37, APG4D,
ILF3, QTRT1, SMARCA4
hsa-mir-7-3,
hsa-mir-199a-1
Tcfe2a,
Evi103,
Evi158
19q13.11 37.57–38.16 0.59 0.97 9 47.3 44 8 7 0 PDCD5, ANKRD27
19q13.12 41.33–41.90 0.57 0.85 11 47.3 43 9 6 0 ZNF146
19q13.2 44.51–44.66 0.15 0.85 8 47.3 43 9 6 0 ZFP36, RPS16, SUPT5H Evi24
19q13.31 49.11–49.85 0.47 0.83 21 46.4 42 9 5 0 ZNF227
19q13.32–19q13.43 53.31–63.07 9.76 0.89 346 49.1 42 12 6 3 FLT3LG, AKT1S1, PSCD2,
RPL18, BAX, RUVBL2,
SNRP70, RPL13A, RPS11,
TBC1D17, NUP62,
NDUFA3, PRPF31, RPS9,
HSPBP1, RPL28, UBE2S,
U2AF2
hsa-mir-150,
hsa-mir-99b,
hsa-let-7e,
hsa-mir-125a,
hsa-mir-371,
hsa-mir-372,
hsa-mir-373
20q12–20q13.12*,A 39.14–43.39 4.25 1.30 43 15 5 11 3 1 TDE1, SFRS6, YWHAB,
PPIA
21q22.3 45.54–46.91 1.37 1.16 17 37.3 27 14 15 6 MCM3AP, C21orf106,
HRMT1L1
For each MCR, the number of NCBI known genes is reported. Number of transcripts is based on Build 35 of the NCBI. Within the amplified MCR, some of the
genes showing both copy number-driven expression and overexpression also in the absence of amplification (Experimental Procedures) are reported (can-
didate genes). MCRs validated by QPCR (asterisks) and/or FISH (black diamonds) identify PS-MCRs. MCR recurrence is denoted as percentage of the total
data set. Only the known genes within the boundaries have been included. Known hotspots for proviral integration residing within MCRs and MCR-containing
microRNAs are indicated. The MCR in 1q was subjected to further fine mapping (Figure S3).for MM cases with or without specific MCRs against KM analy-
ses (data not shown). In other words, we asked whether pres-
ence or absence of a particular MCR was correlated with out-
come, without taking into consideration the gNMF subclass
assignment of the MM samples. This straightforward correlation
identified 14 MCRs associated with poor survival (hereafter des-
ignated as PS-MCR for ‘‘poor-survival’’ MCR) (Table 1, dia-
monds). This PS-MCR list included an amplification on ch8 (in-
cluding MYC) and a deletion on ch17 (including TP53)—bothCANCER CELL APRIL 2006genetic events have been linked to poor prognosis in MM (Kuehl
and Bergsagel, 2002).
Of the remaining amplified PS-MCRs, one resided in the crit-
ical ch1q region and two resided in novel MM loci. The first novel
amplified PS-MCR defined a ch8q24 region spanning 6 Mb with
37 genes (distinct fromMYC) and was notable for its association
with a poor clinical outcome and tumor recurrence in other hu-
man cancer types (Tonon et al., 2005; van Duin et al., 2005).
Among the seven genes showing oncogene-like expression319
A R T I C L ETable 2. High-confidence MCRs in multiple myeloma: Losses and deletions
MCR recurrence
MCRs Gains/losses Amps/dels
Cytogenetic band Position (Mb)
Size
(Mb) Max/min
Known
genes % Tumors
Cell
lines Tumors
Cell
lines Candidate genes miRNA
Integration
sites
1p36.22A 10.413–10.625 0.21 20.98 4 12 6 7 4 0 DFFA
1p35.2A 30.858–31.042 0.18 20.98 4 14 7 8 5 1 LAPTM5
1p32.3–1p32.2A 54.231–57.125 2.89 20.87 23 25 12 16 8 9 SSBP3, USP24
1p13.3–1p12 *,A 111.486–118.215 6.73 21.00 71 41 15 30 13 21 DENND2D, DDX20,
ST7L, PPP2CZ, LRIG2,
PTPN22, CD58, IGSF2
Rap1a, Nras
3p21.31 46.876–47.033 0.16 21.61 5 11 1 11 1 3 CCDC12, HYPB
4q11–4q13.2 52.587–68.443 15.86 20.93 48 19 3 18 3 3 CENPC1, BRDG1 Dkmi9
4q13.3–4q21.1 71.101–76.940 5.84 20.81 51 19 3 18 3 3 RASSF6, MOBKL1A Crlz1
4q22.1* 88.469–89.085 0.62 21.16 10 17 2 17 2 4 IBSP, SPARCL1
4q23 99.844–100.589 0.75 21.70 9 18 3 17 3 3 TM4SF9, METAP1
6p25.3 0.295–0.356 0.06 21.12 2 5 4 1 4 0 DUSP22
8p23.3–8p21.3 0.187–20.123 19.94 20.89 135 28 16 15 13 11 NAT2, RP1L1, PINX1,
TUSC3, DLC1, MTUS1
hsa-mir-124a-1
8p21.3–8p12 22.078–33.573 11.49 20.97 87 33 18 18 14 14 TNFRSF10B, PPP2R2A,
BNIP3L
hsa-mir-320
10q25.1–10q25.2 111.644–112.353 0.71 20.90 6 18 4 16 1 4 MXI1
10q26.2–10q26.3* 128.900–135.241 6.34 21.27 40 18 4 16 2 6 PTPRE, PPP2R2D,
BNIP3, INPP5A
Evi168
11p15.4 5.733–5.799 0.07 23.44 6 15 4 12 2 2 OR52N4, OR52N5,
OR52N1, OR52N2
11q11 55.097–55.176 0.08 23.86 2 7 4 4 2 0 OR4C16, OR4C11,
OR4P4, OR4S2
11q22.1–11q22.2 100.460–102.151 1.69 23.12 14 9 4 6 4 5 PORIMIN, YAP1,
MMP8
11q23.2–11q23.3 112.818–114.552 1.73 20.94 15 5 2 4 2 3 IGSF4
11q24.2–11q24.3* 125.668–128.280 2.61 22.10 12 8 1 8 1 4 ST3GAL4, FLI1,
LOC387820
Fli1 | Ets1
12q13.11–12q13.12 46.814–47.702 0.89 20.80 30 10 4 7 1 2 ANP32D
12q13.2 54.824–54.893 0.07 21.71 5 7 5 3 1 1 SMARCC2
12q14.1–12q14.2 61.013–62.674 1.66 21.02 9 8 3 6 1 1 PPM1H hsa-let-7i
12q23.2–12q23.3 101.334–102.980 1.65 20.90 12 12 3 10 1 4 STAB2 Evi12
13q34 112.239–113.013 0.77 21.01 12 49 32 22 28 16 CUL4A
14q12 29.291–31.655 1.23 20.80 11 32 9 26 7 8 STRN3, HECTD1
14q32.13–14q32.2 93.920–95.630 1.71 20.96 22 33 13 23 9 11 BCL11B Evi151
15q15.1 39.460–39.583 0.12 21.41 5 8 1 8 1 1 NUSAP1
16p13.3 2.102–2.236 0.13 22.07 10 14 7 8 1 2 PKD1, TRAF7, E4F1
16q11.2–16q12.2A 45.173–52.875 7.70 21.71 45 31 23 11 20 6 DNAJA2, SIAH1,
PAPD5, NKD1,
CARD15, RBL2, FTS,
CYLD
16q13A 56.234–56.570 0.14 21.13 9 29 20 12 14 7 GPR56, KATNB1,
KIFC3, CNGB1
16q24.1–16q24.2 83.456–85.894 2.44 21.29 20 31 19 15 13 8 FOXC2, FOXL1 Evi96, Zdhhc7
16q24.3A 88.232–88.627 0.39 21.29 19 31 19 15 9 8 GAS8
17p13.2*,A 3.306–4.791 1.49 21.31 43 23 5 20 2 14 TAX1BP3, GSG2
17p13.1–17p12*,A 6.454–13.921 7.47 21.03 125 30 6 27 2 19 TP53, TNFSF12,
TNFSF13
hsa-mir-195,
hsa-mir-324
Trp53
19q13.33 55.578–55.678 0.10 21.14 5 12 1 12 1 2 POLB1, SPIB
20p12.1A 13.083–17.411 4.33 20.87 21 15 10 7 6 3 OTOR
20q11.21 29.745–30.246 0.50 21.64 13 7 6 2 3 1 FKHL18, DUSP15,
HCK
Bcl2l, Evi47,
Cri07
20q13.12A 43.967–44.107 0.14 21.08 6 12 8 5 4 1 PCIF1
21p11.2–21p11.1 9.932–10.167 0.24 21.11 3 6 1 6 1 1 TPTE
22q11.23 22.638–23.065 0.43 21.59 10 25 12 15 2 6 DKFZP434P211
For each MCR, the number of NCBI known genes is reported. Number of transcripts is based on Build 35 of the NCBI. MCRs validated by QPCR (asterisks) and/or
FISH (black diamonds) identify PS-MCRs. Potential tumor suppressor genes residing within the MCRs are indicated. Known hotspots for proviral integration re-
siding within MCRs and MCR containing microRNAs are indicated. The MCR at 11q11 has recently been shown by Sebat et al. (2004) to be a copy number
polymorphism (ORF511, ch11q11).pattern are DEPDC6 and FBXO32. The second novel amplified
PS-MCR targets a ch20q region (43 genes) that is associated
with disease progression and metastases in prostate cancer
(Wullich et al., 2004), esophageal squamous cell carcinoma,320and gastric and colorectal adenocarcinoma (Fujita et al.,
2003). In this amplicon resides PPIA (Cyclophilin A), which func-
tions as a paracrine and autocrine modulator of endothelial cells
proliferation, migration, and invasive capacity (Kim et al., 2004).CANCER CELL APRIL 2006
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mapped to ch1p within a much larger, less defined region impli-
cated in MM prognosis based on FISH analyses (Panani et al.,
2004). Two loci contain only four genes including DFFA, a key
caspase-3 substrate that triggers DNA fragmentation during ap-
optosis (Table 2). The remaining deletion PS-MCRs include
three on ch16, two on ch17—one of them harboring TP53 (Table
2)—and two on ch20. Among these, the 16q12 region (45 genes)
includes the tumor suppressor CYLD. The 16q13 region con-
tains only five genes: G protein-coupled receptor 56, G pro-
tein-coupled receptor 97, two genes encoding the centrosomal
proteins KATNB1 and KIFC3, and the hypothetical protein
encoding gene C16orf50. Finally, the ch17p13.3–13.2 locus
spanning 1.49 Mb with 43 genes includes several prime tumor
suppressor candidates such as TAX1BP3, a Wnt/b-catenin sig-
naling pathway inhibitor (Kanamori et al., 2003), andGSG2, a ki-
nase required for mitotic histone H3 Thr 3 phosphorylation and
normal metaphase chromosome alignment (Dai et al., 2005).
In summary, the triangulation of aCGH, expression profiles,
and clinical annotation has identified genomic regions and can-
didate oncogenes and TSGs with plausible links to MM disease
progression and clinical outcome.
Discussion
In this study, unsupervised classification of MM by gNMF de-
fined four genomically distinct subclasses, revealing a level of
molecular heterogeneity not previously appreciated for this dis-
ease. Additionally, a compendium of focal and recurrent genetic
lesions, a subset of which is linked to poor prognosis, has been
identified. Finally, integration of expression data with genomic
and clinical information has further delimited a list of prime onco-
gene candidates residing within the amplified MCRs.
Distinct molecular subclasses linked to disease
pathogenesis and prognosis
This study demonstrates that embedded within the aCGH pro-
files are biologically significant patterns of genomic alterations.
gNMF with rank of K = 2 divided the MM primary tumors into kA
versus kB subgroups corresponding to the traditional hyperdip-
loid and nonhyperdiploid groups, respectively (Figure 1). Al-
though the lack of a significant outcome difference between
these two subgroups may relate to sample size and/or time of
clinical follow up (median 43 months), the fact that further strat-
ification with rank K = 4 resulted in distinct subclasses with dif-
ferences in clinical outcome (Figure 2 and data not shown) indi-
cates that the more likely explanation relates to inherent
heterogeneity within the previously defined hyperdiploid and
nonhyperdiploid groups. Indeed, when hyperdiploid MM cases
were stratified into two subclasses, k1 and k2, a clear survival
advantage was observed among patients in the k1 group (Fig-
ure 2), which was characterized by presence of ch11 gain and
absence of ch1q gain or ch13 loss. Importantly, by reducing
the k1 versus k2 classifier to presence/absence of ch1q and
ch13 alterations determined by FISH in hyperdiploid MM (i.e.,
tumor samples with odd-chromosome gain pattern as deter-
mined by average of gene expression values across chromo-
somal arms), we were able to validate the prognostic difference
of k1 and k2 in an independent cohort of 135 outcome-anno-
tated TT2-treated MM cases (Barlogie et al., 2006) (Figure S4).
A further validation of the biological significance of k1 and k2CANCER CELL APRIL 2006subclasses was provided by gene set enrichment analysis
(GSEA) (Monti et al., 2005) of the transcriptomes, revealing per-
turbation of distinct cancer-relevant pathways in each subclass.
While TP53, KRAS, FRAP1, and the proteasome pathways were
altered in both subgroups (data not shown), dysregulation of ad-
ditional cancer-relevant pathways, such as sonic hedgehog and
RAC1 (Mitsiades et al., 2004; Qiang et al., 2005), was observed
only in k2 samples, consistent with a more advanced evolution
of MM. However, it should be emphasized that, although hyper-
diploid MM stratified into good or poor prognosis subgroups
based on well-known genomic features bearing obvious imme-
diate translational implications, the broad prognostic relevance
of these gNMF subclasses will require stringent validation in
prospective clinical trials, where the impact of sampling bias,
therapy-specific outcome, and/or other confounding factors
can be investigated.
To identify key genes within ch1q or ch13 that may dictate clin-
ical behavior of hyperdiploid MM, we integrated gene expression
data with copy number profiles to generate a short list of strong
candidates (Tables S2 and S3). Among the 1q genes upregulated
in k1 versus k2 are many that have not been previously linked to
any cancer and that affect survival and proliferation, hypoxia,
and cell adhesion and motility (Table S2). Regarding ch13 dele-
tion, most reported cases show loss of the entire chromosome,
although w15% of MM patients sustain more focal deletion or
LOH targeting ch13q14 (Elnenaei et al., 2003). Our integrated
RNA-DNA analysis was able to narrow the region of interest to
a 10 Mb region on ch13q14, encompassing some interesting
candidates. RB1 was included in this region; however, its role
in MM has been questioned even in advanced MM and cell lines
(Kuehl and Bergsagel, 2002; Shaughnessy et al., 2003). Among
the downregulated genes within this region are several putative
TSGs (Table S3). While integration of expression and copy num-
ber provides an effective means to convert genomic features into
candidate genes, it should be emphasized that such genome-
anchored analysis will preferentially capture genes whose dys-
regulation and involvement in MM are driven by copy number
aberrations, while missing other MM-relevant genes that are
predominantly regulated by other mechanisms.
MCRs harbor candidate genes of biological
and clinical relevance
Most highly recurrent focal MCRs identified in this study are
novel, and several possess clinical relevance (Figure 4 and Ta-
bles 1 and 2). It should be noted that our genomic approach pri-
marily emphasized regions and genes within defined MCRs, and
therefore genes residing outside of MCRs that might be related
to prognosis would not be captured by our analysis. Interest-
ingly, the MM genome shared many CNAs with other histologi-
cally unrelated cancers such as pancreas, lung, breast, and
ovary, suggesting common mechanisms of disease pathogene-
sis (Aguirre et al., 2004; Cheng et al., 2004; Tonon et al., 2005).
Also, several known hotspots for proviral integration and/or
chromosomal rearrangement targeting pathogenetic loci were
located within high-priority MCRs (Tables 1 and 2) (Collier
et al., 2005).
The integration of copy number changes and gene expression
information (using bone marrow-derived plasma cells as refer-
ence) enabled significant reductions in the number of candidate
oncogenes residing within the high-priority MCR amplicons. The
reliability of this approach is confirmed by the ability of this321
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rounding, likely bystander genes. For instance, HGF was lo-
cated within a small MCR including four genes and was found
to be the only gene with such an oncogene-like expression pat-
tern. It should be noted that microRNAs embedded within the
MCRs could also exert an oncogenic role, as recently demon-
strated (He et al., 2005). Indeed, 20% of the 87 high-priority
MCRs contain microRNAs that could therefore represent the
key genetic element of the CNA.
Among candidates from other MCRs exhibiting oncogene-like
expression are components of prominent cancer pathways (Ta-
ble 1). The amplification and overexpression of E3 ubiquitin li-
gases and two DEAD box proteins on ch11 and ch17 are intrigu-
ing given the critical role of the ubiquitin-proteasome pathway in
auditing the levels of key cell cycle and apoptosis control pro-
teins (Nakayama and Nakayama, 2005) and the proposed role
of human RNA helicases in various types of cancer (Abdelha-
leem, 2004). Interestingly, in the amplified PS-MCR on ch20,
among the genes showing an oncogene-like expression pattern,
there was PPIA (Cyclophilin A) which functions as a paracrine
and autocrine modulator of endothelial cell proliferation, migra-
tion, and invasive capacity (Kim et al., 2004).
Among the TSGs, TP53 resided in an MCR that was also
linked to poor prognosis, confirming previous reports (Bergsa-
gel and Kuehl, 2005). Interestingly, TP53 was generally overex-
pressed (data not shown), a finding consistent with upregulation
of mutant p53 (Furubo et al., 1999). CDKN2C and CDKN1B, of-
ten deleted in MM (Bergsagel and Kuehl, 2005; Filipits et al.,
2003), were not included in the high-priority MCR list, since
the segmentation algorithm discards CNAs identified by single
probes in exchange for an improved false positive rate (Aguirre
et al., 2004); however, they were recurrently lost in the raw CGH
profiles (Figure S3 and data not shown). As expected, CDKN2A
and PTEN did not show copy number losses, as they are usually
inactivated in MM through promoter methylation and point mu-
tations, respectively (Chang et al., 2006; Urashima et al., 1997).
In addition, several bona fide and putative TSGs not previously
linked to MM were identified (Table 2).
In conclusion, the application of gene-specific CGH plat-
forms, custom bioinformatic tools, and expression profiles has
identified many recurrent amplifications and deletions that sig-
nificantly alter expression of specific subsets of genes. The
high degree of MM genomic complexity and the common tar-
geting of the same loci in other tumor types support the view
that a large number of important oncogenes and TSGs remain
to be identified. This integrated view of the MM genome is con-
sistent with the concept of widespread changes in the expres-
sion of genes with cancer activity in the pathogenesis of MM,
a concept with therapeutic and diagnostic implications for MM
in particular and cancer in general.
Experimental procedures
Primary tumor genomic DNA and MM cell lines
Genomic DNA from primary tumors derived from the Donna and Donald Lam-
bert Laboratory of Myeloma Genetics, Myeloma Institute for Research and
Therapy, University of Arkansas for Medical Sciences (n = 67) (Barlogie
et al., 2006). Patients were treated with the TT2 Protocol (median follow-up
43 months, range: 5 months to 65 months) (Barlogie et al., 2006) (Table
S1). MM cell lines were collected at Genetics Branch, NCI (Michael Kuehl),
Weill Medical College and Graduate School of Medical Sciences of Cornell
University (Leif Bergsagel), and Jerome Lipper Multiple Myeloma Center,322the Department of Medical Oncology, DFCI (K.C.A.) (G.T. and R.A.D., unpub-
lished data). The Institutional Review Board of the University of Arkansas for
Medical Sciences approved the research studies, and all subjects provided
written informed consent approving use of their samples for research pur-
poses.
aCGH profiling
Primary tumor DNA was obtained from CD138-enriched cell populations us-
ing CD138 magnetic microbeads (Miltenyi Biotec Inc.). Genomic DNA from
cell lines and primary tumors were extracted according to manufacturer in-
structions (Gentra System Inc.). Genomic DNA was fragmented and ran-
dom-prime labeled as previously described (Tonon et al., 2005) and hybrid-
ized to either human cDNA or oligo microarrays. All MM cell lines were
analyzed using a cDNA array platform (Aguirre et al., 2004), while the 67 pri-
mary tumors were analyzed using the oligonucleotide array platform
(Brennan et al., 2004; Tonon et al., 2005). The cDNA microarray contains
14,160 cDNA clones (Agilent Technologies, Human 1 clone set) with
13,281 genome-mappable clones, for which approximately 11,211 unique
map positions were defined (NCBI, Build 35). The median interval between
mapped elements is 0.73 Mb, 94.1% of intervals are less than 1 Mb, and
98.9% are less than 3 Mb. The oligo array contains 22,500 elements de-
signed for expression profiling (Agilent Technologies, Human 1A V2), for
which 16,097 unique map positions were defined (NCBI, Build 35). The me-
dian interval between mapped elements is 0.55 Mb, 96.7% of intervals are
less than 1 Mb, and 99.5% are less than 3 Mb. Fluorescence ratios of
scanned images of the arrays were calculated as the average of two paired
arrays (dye swap), and raw aCGH profiles were processed to identify statis-
tically significant transitions in copy number using a segmentation algorithm,
as described (Aguirre et al., 2004; Olshen et al., 2004). The data are centered
by the tallest mode in the distribution of the segment values. After mode-cen-
tering, we defined gains and losses for the oligonucleotide data set as log2
ratiosR +0.11 or20.11 (64 SD of the middle 50% quantile of data) and am-
plification and deletion as a ratio >0.4 or <20.4, respectively. For the cDNA
data set, gains and losses were defined as log2 ratios of R+0.13 or 20.13
(64 SD of the middle 50% quantile of data) and amplification and deletion
as a ratio >0.5 or <20.5, respectively. The segmented log2 ratio distributions
and thresholds chosen are shown in Figure S4D. The narrow central peak
sharply defines ‘‘normal’’ copy number for a sample (most common chromo-
somal copy number, not necessarily diploid). Thus ‘‘abnormal’’ (relative gain/
loss) is well defined by tight thresholds (64 SD of the middle 50% quantile).
The aCGH data discussed in this publication are available as Supplemental
Data and at http://genomic.dfci.harvard.edu/array_cgh_db.htm.
Adaptation of the NMF algorithm to aCGH analysis and Fisher’s
exact test
The algorithm used for aCGH analysis is a modification of NMF that entails
conversion of aCGH data followed by NMF-based classification (C.B. and
L.C., unpublished data). NMF is a method designed to reduce data dimen-
sionality based on matrix decomposition by parts, and it has recently been
shown to be effective in elucidating meaningful structure inherent in gene ex-
pression data sets: organizing both the genes and samples to provide biolog-
ically or clinically relevant correlations (Brunet et al., 2004). Only segmented
aCGH data and the 67 primary tumor samples were analyzed. Briefly, the
aCGH data set was first dimension reduced by eliminating redundant probes,
defined as two or more probes showing identical segmented values in all
samples. In this manner, 16,084 mapped probes were reduced to 942 geno-
mic regions of unique segmented values. The reduced aCGH data (67 sam-
ples by 942 regions) were converted to nonnegative values by assigning two
dimensions to each of the regions: a ‘‘gain’’ dimension for log2 ratios greater
than zero, and a ‘‘loss’’ dimension for the absolute value of log2 ratios less
than zero. The resultant data set is a nonnegative matrix of dimension
67 3 1884, which is subject to NMF using the software package (Brunet
et al., 2004) and run in MATLAB (The MathWorks, Inc.). For each factor level
two through six, NMF is repeated 1000 times to build a consensus matrix,
and this is used to assign samples to clusters based on the most common
consensus. As a measure of stability, the cluster assignments were repeated
with a random 10% of the samples excluded on each iteration, and a nearly
identical clustering was observed.
Fisher’s exact test was used to identify genomic regions presenting signif-
icantly different occurrence of copy number gains or losses between k1 andCANCER CELL APRIL 2006
A R T I C L Ek2 groups. Briefly, for each sample, each of the 942 genomic regions was
classified as having copy number normal, gained, or lost based on log2 ratio
thresholds of60.13. Then, a 23 2 contingency table was tested for k1 versus
k2 samples gained versus normal; a second matrix tested lost versus normal.
Fisher’s exact test p values were corrected for multiple testing (‘‘qvalue’’
function, R package ‘‘qvalue,’’ http://cran.r-project.org/).
Expression profiling on Affymetrix GeneChip
Detailed protocols for RNA purification, cDNA synthesis, cRNA preparation,
and hybridization to Affymetrix H133A and H133Plus2.0 GeneChip microar-
rays were performed as described (Zhan et al., 2003). As control, RNA was
derived from CD138-selected bone marrow-derived plasma cells from 12
healthy donors, as described (Zhan et al., 2003). The genomic positions for
each gene were mapped based on NCBI Build 35 of human genome. SAM
was performed as described (Tusher et al., 2001). The data discussed in
this publication have been deposited in NCBI’s Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE4452.
Integrated copy number and expression analysis
For each gene probe set falling within an amplified MCR, two different anal-
yses of gene expression were conducted: (1) expression in tumors with CNA
compared to normal plasma cells, and (2) expression in tumors without CNA
compared to normal plasma cells. Because of the widely varying proportion
of copy number-altered samples in each MCR, SAM was impractical to apply
generally to the two measures. Thus, all expression comparisons were in-
stead performed using the same ‘‘gene weight’’ measure, similar to T score,
as described below and in previous publications (Aguirre et al., 2004; Hyman
et al., 2002). For each gene probe set, gene weight (GW) of expression values
for test set ‘‘T’’ compared to reference set ‘‘R’’ is calculated by
GWT versus R =
T 2R
sT +sR
Significance was determined by permuting sample labels for expression
data (1000 permutations, p value% 0.001).
GSEA
GSEA has been described elsewhere (Mootha et al., 2003). Briefly, the
method requires two inputs: (1) a list of genes that have been ranked accord-
ing to expression difference between two states and (2) a priori defined gene
sets (e.g., pathways), each consisting of members drawn from this list. The
95 pathways were derived from Monti et al. (2005) and Mootha et al.
(2003). No normalization was applied to the data. The ranking metric used
was Signal2Noise, with a weighted ES scoring scheme. The phenotype
was permuted with 1000 permutations.
QPCR verification and FISH
PCR primers were designed to amplify products of 100–150 bp within target
and control sequences as described (Aguirre et al., 2004). Metaphase spread
slides were prepared following standard protocols (Protopopov et al., 1996).
The BACs RPC11 HS (ch1, spanning BCL9), RP11-180M15 (ch12, spanning
CDKN1B), and RP11-237C13 were used for hybridizations. The probes for
FISH were labeled using nick translation, according to manufacturer’s in-
structions (Roche Molecular Biochemicals) with either biotin-14-dATP or di-
goxigenin-11-dUTP. Biotinylated probes were detected using Cy3-con-
jugated avidin (Accurate Chemical). For digoxigenin-labeled probes,
antidigoxigenin-FITC Fab fragments (Enzo Life Sciences) were used. Slides
were counterstained with 5 mg/ml DAPI (Merck) and mounted in Vectashield
antifade medium (Vector Laboratories). FISH signal acquisition and spectral
analysis were performed using filter sets and software by Applied Spectral
Imaging.
Automated MCR definition
Loci of amplification and deletion are evaluated across samples with an effort
to define MCRs targeted by overlapping events in two or more samples.
An algorithmic approach has been previously described (Aguirre et al.,
2004; Tonon et al., 2005). It is applied to the segmented data as follows:
(1) Segments with values >0.4 or <20.4 (0.5 and 20.5 for cDNA) are
identified as altered.CANCER CELL APRIL 2006(2) If two or more similarly altered segments are adjacent in a single profile
or separated by <0.5 Mb, the entire region spanned by the segments is
considered to be an altered span.
(3) Altered segments or spans <20 Mb are retained as ‘‘informative spans’’
for defining discrete locus boundaries. Longer regions are not
discarded, but are not included in defining locus boundaries.
(4) Informative spans are compared across samples to identify overlapping
amplified or deleted regions (informative spans only); each is called an
‘‘overlap group.’’
(5) Overlap groups are divided into separate groups wherever the
recurrence rate falls <25% of the peak recurrence for the whole
group. Recurrence is calculated by counting the number of samples
with alteration at high threshold (60.4, or 0.5 and 20.5 for cDNA).
(6) MCRs are defined as contiguous spans within an overlap group, having
at least 75% of the peak recurrence. If there are more than three MCRs
in a locus, the whole region is reported as a single complex MCR. In
cases where MCRs are defined by two overlapping CNAs, MCR
inclusion in the final list and boundary definition is subjected to
individual review.
Identification of prognostic MCRs
As described above for NMF analysis, for each unique genomic region in the
aCGH (segmented data), the samples are divided into those that have copy
gain versus the rest, and those that have copy loss versus the rest. This is
based on a low threshold of log2 = 0.13. For each genomic region, KM sur-
vival was calculated for each pair of altered/unaltered groups. The survival
curves were tested for significant difference via log rank test (survdiff func-
tion, Survival package, http://cran.r-project.org/). The regions showing a p
value of%0.05 were then mapped to the MCRs.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and three supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/9/4/313/DC1/
.
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